Mitochondrial Metabolism Turns On Inflammatory Genes in Aging Cells
New Nature papers show that blocking the mitochondrial citrate transporter SLC25A1 cuts the acetyl-CoA supply that enables inflammatory gene activation, pointing to a drug strategy to reduce harmful age‑related inflammation.
Overview
- This week, a coordinated seven‑paper series published across Nature journals identified a mitochondrial–epigenetic pathway that helps senescent cells drive chronic inflammation.
- Researchers found senescent cells boost mitochondrial production of acetyl‑CoA, and that acetyl‑CoA fuels histone acetylation that makes inflammatory (SASP) genes more accessible and active.
- The team nominated the mitochondrial citrate transporter SLC25A1 as a druggable control point because blocking it lowered acetyl‑CoA, reduced histone acetylation at SASP sites, and dampened inflammatory gene expression in models.
- Alongside the mechanism papers, authors validated the SenMayo gene set and biomarkers such as IL‑23R to better detect diverse senescent cells, and they mapped senescent cell types across tissues.
- Multiple preclinical interventions including senolytic drugs, a tomato‑derived compound, and genetic approaches reduced inflammation and improved frailty and brain measures in aged mice but human safety and efficacy remain untested.